{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+Placebo", "query": { "intervention": "Baricitinib Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Baricitinib+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-12T17:36:40.823Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03616912", "title": "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2018-08-02", "completion_date": "2022-03-09", "has_results": true, "last_update_posted_date": "2023-01-30", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03616912" }, { "nct_id": "NCT04421027", "title": "A Study of Baricitinib (LY3009104) in Participants With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1525, "start_date": "2020-06-12", "completion_date": "2021-06-10", "has_results": true, "last_update_posted_date": "2022-07-28", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 25, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Newport Beach, California + 20 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04421027" }, { "nct_id": "NCT03742973", "title": "A Study of Baricitinib (LY3009104) in Participants With Primary Biliary Cholangitis Who do Not Respond or Cannot Take UDCA", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Biliary Cholangitis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-03-28", "completion_date": "2019-09-26", "has_results": true, "last_update_posted_date": "2020-10-14", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 10, "location_summary": "Coronado, California • Sacramento, California • Aurora, Colorado + 7 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742973" }, { "nct_id": "NCT03435081", "title": "A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 440, "start_date": "2018-02-20", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2022-09-09", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 60, "location_summary": "Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435081" }, { "nct_id": "NCT06631287", "title": "Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Long COVID", "Sars-CoV-2 Infection", "Coronavirus Infections", "COVID-19" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wes Ely", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2024-10-21", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06631287" }, { "nct_id": "NCT07222137", "title": "A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "35 Years", "sex": "ALL", "summary": "1 Year to 35 Years" }, "enrollment_count": 150, "start_date": "2026-01-12", "completion_date": "2031-07", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 8, "location_summary": "Santa Barbara, California • Tallahassee, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Santa Barbara", "state": "California" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "West Des Moines", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT07222137" }, { "nct_id": "NCT02708095", "title": "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2016-03-24", "completion_date": "2017-11-09", "has_results": true, "last_update_posted_date": "2018-11-21", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 27, "location_summary": "Tucson, Arizona • Beverly Hills, California • Covina, California + 22 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02708095" }, { "nct_id": "NCT04401579", "title": "Adaptive COVID-19 Treatment Trial 2 (ACTT-2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Placebo", "type": "OTHER" }, { "name": "Remdesivir", "type": "DRUG" }, { "name": "Baricitinib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 1033, "start_date": "2020-05-08", "completion_date": "2020-07-31", "has_results": true, "last_update_posted_date": "2022-03-14", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 53, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 44 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04401579" }, { "nct_id": "NCT01711359", "title": "A Study in Participants With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Baricitinib Placebo", "type": "DRUG" }, { "name": "MTX Placebo", "type": "DRUG" }, { "name": "Folic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 588, "start_date": "2012-11", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2019-09-19", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 47, "location_summary": "Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 44 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01711359" }, { "nct_id": "NCT03616964", "title": "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 778, "start_date": "2018-08-02", "completion_date": "2021-10-20", "has_results": true, "last_update_posted_date": "2022-11-23", "last_synced_at": "2026-09-12T17:36:40.823Z", "location_count": 39, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 33 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03616964" } ] }